Globes Reports on BioSight’s Positive Trial Results

BioSight reports positive leukemia drug trial

After receiving a $13 million investment, BioSight reports successful interim results in trial of its Leukemia treatment product.

Cancer treatment company BioSight, which recently received a $13 million investment from Mori Arkin and US investment fund Primera Capital, reports positive interim results of an initial efficacy trial for its Leukemia treatment product.

The company’s product, Astarabine, had been tested on 15 Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) patients unfit for chemotherapy, due to its toxicity. While it is impossible to discuss the significance of the results, since the trial was conducted with no control group (as customary with trials on cancer at this stage), results indicate a good response to treatment in the examined group, with minimum side effects. In three out of 15 patients, for whom no treatment could earlier be provided, a full remission was noted for 4-10 months, to date; in two further patients a partial remission was reported for 3-7 months.

Read the full article (Globes English).

 

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+